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Abstract
Angiogenesis is a crucial process in tumor pathogenesis as it sustains malignant cells with nutrients and oxygen. It
is well known that tumor cells secrete various growth factors, including VEGF, which triggers endothelial cells to
form new capillaries. Prevention of expansion of new blood vessel networks results in reduced tumor size and
metastasis. Production of VEGF is driven by hypoxia via transcriptional activation of the VEGF gene by HIF-1a.
Tumours are now understood to contain different types of cells, and it is the cancer stem cells that retain the
ability to drive the tumour’s growth. They are called cancer stem cells because, like stem cells present in normal
tissues of the body, they can self-renew and differentiate. These cancer stem cells are responsible for the relapse of
cancer as they are found to be resistant to conventional modes of cancer therapy like chemotherapy and radiation.
In this review, a novel mode of treatment of cancer is proposed, which utilizes the twin nanoparticle to target
endothelial cells in the niche of cancer stem cell. The nanoparticle discussed in this review, is a twin nanoparticle
of iron coated with gold, which targets VEGF positive cell in the vicinity of cancer stem cell. In the twin
nanoparticle, one particle will recognize cancer stem cell, and another conjugated nanoparticle will recognize VEGF
positive cells, thereby inhibiting endothelial cells in the proximity of cancer stem cell. This novel strategy will inhibit
angiogenesis near cancer stem cell hence new tumour cannot grow and old tumour will be unable to metastasize.
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Introduction
Angiogenesis is the formation of new blood vessels from
the pre-existing vasculature. It is an important process
as the blood delivers oxygen and nutrients for the survi-
val of cells and their functioning. It has been reported
that in the absence of blood vessel formation, the tumor
mass does not grow more than 1-2 mm in size and also
the cells from the primary tumor cannot escape and
metastasize.
Angiogenesis is controlled by pro-angiogenic and anti-
angiogenic factors in the body. The regulatory factors
may be several growth factors like VEGF, FGF, PDGF,
EGF, placental growth factor, Angiopoietin-1, Angio-
genin, Interleukin 8 etc. The natural anti-angiogenic fac-
tor presents in the body are Angiostatin, Endostatin,
Vasostatin, Prolactin, Angiopoietin-2, Interferon, -a and
g Interleukin 12, Fibronectin, Platelet factor-4, etc. A
finely tuned equilibrium exists between these pro-angio-
genic and anti-angiogenic factors in vivo [1].
Angiogenesis is driven due to hypoxic conditions in the
tumor. The hypoxic condition activates the production of
VEGF (Vascular Endothelial Growth Factor) which then
binds to the VEGF receptor (VEGFR), a transmembrane
receptor tyrosine kinase on the membrane of endothelial
cells and activates them by phosphorylation of tyrosine
kinase (TK). The TKs are also present on the receptors
of FGF, PDGF, Ang-1, Ang-2, and HGF along with that
of VEGF and leads to angiogenesis [1]. The activation of
VEGFR on endothelial cells leads to the formation of a
blood vessel and oxygenation of tumour, which in turn
leads to growth of tumour size (as shown in Figure 1).
We are especially focusing on VEGF as it has been well
proven to inhibit tumour growth upon tagging with sin-
gle nanoparticle. The role of other growth factors has not
been well studied so far to prove that they alone can inhi-
bit tumour growth. In this review, we are discussing
about the role of VEGF in tumor progression near cancer
stem cells and targeting it using twin nanoparticles.
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VEGF Inhibitors
VEGF is a heparin binding homodimeric glycoprotein
that binds to endothelial specific transmembrane recep-
tors tyrosine kinases. The VEGF family contains differ-
ent types of VEGF like, VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E and P1GF (placenta growth factor).
The receptors of VEGF are named as Flt-1 (VEGFR-1),
KDR/Flk-1 (VEGFR-2), FLT-4 (VEGFR-3) [2]. VEGFR-1
and VEGFR-2 are involved in angiogenesis whereas the
VEGFR-3 is involved in lymphangiogenesis [3].
A number of studies have shown that the overexpres-
sion of VEGF and VEGFR are associated with tumor
growth, progression and metastatis. Metastatic tumor
has been known to secrete VEGF to induce the neovas-
cularization [4]. There are three types of VEGF recep-
tors namely VEGFR-1, 2 and 3 and there are different
types of ligand that binds to these three receptors as
listed in Table 1. VEGF A, B and P1GF binds to
VEGFR-1 [5-8]. VEGF A, B,C,D binds to VEGFR-
2 [9-11] and VEGF C and D binds to VEGFR-3 [12,13].
We understand that different tumour express different
types of VEGF and VEGFR. Table 2 also shows that dif-
ferent VEGF inhibitors have been targeted against differ-
ent VEGFR till now. Therefore, twin nanoparticle will
target only the tumour specific VEGF and VEGFR.
The VEGF pathway is a good target for the anti-angio-
genic therapy for various reasons like-
1. It is produced in large quantities by growing pri-
mary tumors.
2. VEGF pathway induces the production of sprout-
ing blood vessels.
3. VEGF binds to endothelial cells involved in the
formation of blood vessels. Also endothelial cells are
genetically stable and spontaneous mutations are
rare when compared to unstable tumor cells.
Figure 1 A pathway regulating tumour growth i.e. cancer stem cells trigger tumour growth in response to hypoxic condition and
releases the signal VEGF. The VEGF initiates the endothelial cell to proliferate and form blood vessels to vascularize the growing tumour. As
soon as the tumour gets oxygenated, the tumour grows further in size.
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4. VEGFR are expressed in low levels in normal
cells, and extensively in tumor cells [14].
Several preclinical studies and clinical trials of phase I
and phase II using both monoclonal antibodies against
VEGF and VEGFR pathways have proven that these
agents are safe. These agents are also of great potential
in cancer therapy in patients by blocking the angiogen-
esis pathway thus restricting the tumor mass and redu-
cing the possibility of metastasis [15,16].
There are various inhibitors available which target the
VEGF pathway. Bevacuzimab is a humanized monoclo-
nal antibody which binds to VEGF-A [17,18] before it
can attach to its receptor VEGFR1 and VEGFR2, thus
blocking the pathway. Another monoclonal antibody
used to target VEGF pathway is IMC-1121B which
selectively binds and inhibits the VEGFR-2 [19]. It is a
chimeric IgG1 antibody and its binding prevents the for-
mation of ligand- receptor complex and thus inhibits
the dimerization and phosphorylation of tyrosine kinase.
There are several tyrosine kinase inhibitors which pre-
vent the phosphorylation of the tyrosine kinase thus
blocking the angiogenesis. Some of the examples are
given in Table 2 like, CDP-791 targets VEGFR-2 [20]
and there are several tyrosine kinase inhibitors namely
PTK-787 [21], AEE788 [22], ZD6474, AG013736 [23,24],
AZD2171 [25], SUO11248 [26], CP-547,632 [27],
GW786024 [28], Bay 93-4006 [29], AMG 706 [30].
Bevacuzimab has shown good tolerance in patients in
preclinical and early clinical studies. Although it has
shown some side effects such as hypertension and risk of
thromboembolism due to toxicity, but clinical efficiency
has also been demonstrated [31].
The VEGF inhibitors will not be specific to the tumor
cells as the normal cells also contain VEGF and VEGFR
though in less concentration than in the tumor cells where
it is overexpressed due to hypoxic conditions. These
hypoxic conditions lead to the expression of a transcrip-
tion activator hypoxia inducible factor alpha (HIF-1a).
HIF-1a has also been found in cancer stem cells and
hence it is an effective way of targeting the drug or mono-
clonal antibody via the use of nanoparticle [32]. The nano-
particle could be gold, iron, which encapsulates the drug/
monoclonal antibody [33]. Although VEGF/VEGFR is also
found in normal cell, one cell i.e. unique to tumour is can-
cer stem cell. Therefore, it is important to target VEGF in
the vicinity of cancer stem cell(s).
Cancer stem cells and their markers
The most exciting research in the cancer therapy is the
targeting of cancer stem cells (CSC). There has been evi-
dence that the growth and propagation of the cancer is
dependent on the small subset of cells which are cancer
stem cells [34]. These stem cells are present in the stem
cell niche which functions to maintain these cells. Several
extrinsic factors are generated by these niches which are
responsible for stem cell growth and proliferation and
play an important role in a self-renewal and regulate the
fate of lineage [35,36]. Stem cells also have the higher
degree of proliferation, a longer life span compared to
their progeny and a higher tendency to undergo muta-
tion. Any mutation in the pathways that control these
stem cells may lead to impaired stem cell function and
thus leading to uncontrolled proliferation and impaired
differentiation. These cells are also believed to be
involved in the relapse of the cancer in an individual for
e.g. in hematopoietic malignancies. These stem cells are
similar to normal stem cells in the following ways- 1)
they have the ability to self- renew, 2) they have the
potential to differentiate into heterogeneous daughter
cells, 3) they can proliferate extensively and give rise to a
Table 1 Types of VEGFR and VEGF
Type of
VEGFR
Binds to Location of expression Reference
VEGFR-1 VEGF-A, VEGF-B, P1GF Thymus, monocytes, macrophages, dendritic cells, osteoclast, astrocytes [5-8]
VEGFR-2 VEGF-A, VEGF-B,
VEGF-C, VEGF-D
Vascular endothelial progenitors cells, heamatopioetic stem cells, Neuronal cells, osteoblasts,
osteoclast, pancreatic duct cells, retinal progenitor cells, megakaryocytes
[9-11]
VEGFR-3 VEGF-C, VEGF-D Lymphatic endothelial cells, capillaries and veins in endocrine organs, monocytes and macrophages,
neural progenitor cells
[12,13]
Table 2 List of VEGF Inhibitors
Agent Class Target References
Bevacuzimab MAB VEGF-A [17,18]
IMC-1121B MAB VEGFR-2 [19]
CDP-791 DiFabPEG VEGFR-2 [20]
CEP-7055 TKI VEGFR-1,2,3 [20]
PTK-787 TKI VEGFR-1,2 [21]
AEE788 TKI VEGFR-2, EGFR [22]
ZD6474 TKI VEGFR-1,2,3, EGFR [23]
AG013736 TKI VEGFR-1,2 [24]
AZD2171 TKI VEGFR-1,2 [25]
SUO11248 TKI VEGFR-1,2, PDGFR [26]
CP-547,632 TKI VEGFR-1,2 [27]
GW786024 TKI VEGFR-1,2,3 [28]
Bay 93-4006 TKI VEGFR-1,2, PDGFR [29]
AMG 706 TKI VEGFR-1,2,3 [30]
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complete new tumour from one cell [37]. These CSCs are
highly tumourigenic and the main concern about them is
that they are resistant to conventional treatment like che-
motherapy [38,39]. This has been stated as the cause for
tumor relapse as these cells are not destroyed [40]. VEGF
is also targeted in the niche vasculature with the help of
drugs like Bevacizumab [41], but the major problem is a
blockage of VEGF or angiogenesis in normal cells also
[42,43]. Therefore, in this review, we try to design a novel
cancer therapy method that can be used to target angio-
genesis near these cancer stem cells to prevent the recur-
rence of tumor. Although, there is a problem in
recognizing tissue-specific cancer stem cell, we have a list
of cancer stem cell marker available based on the
research conducted, until now. These markers may be a
novel target for targeting the CSCs and avoiding the pos-
sibility of recurrence and metastasis in various
carcinomas.
There are different types of cancer stem cell marker
which varies with the organ. Some lists of the organ spe-
cific cancer stem cells markers which are present on the
surface are summarized in Table 3. CD44/CD24, CD29,
CD133, CD200 are the cancer stem cell marker for breast
cancer [44-47]. CD44, CD24, ESA, CD133, CXCR4 are
the cancer stem cell marker for pancreatic cancer
[48-50]. Stro-1, CD105, CD44 are the cancer stem cell
marker for bone cancer [51]. EpCAM, CD44, CD166,
CD133 are the cancer stem cell marker for colorectal
cancer [52,53]. CD133, CD44, Integrin 12b1 are the can-
cer stem cell marker for prostate cancer [54]. CD90,
CD133 are the cancer stem cell marker for liver cancer
[55]. CD133, CD200 are the cancer stem cell marker for
brain cancer [56,57]. CD44, BMI-1 are the cancer stem
cell marker for head and neck cancer [58,59].
In this review we are discussing about a nanoparticle
which is specific to cancer stem cells markers and also
carries VEGF monoclonal antibody, thus inhibiting the
process of angiogenesis in the vicinity of cancer stem
cells. This strategy will reduce the recurrence of cancer
as it inhibits angiogenesis in proximity of cancer stem
cells as shown in Figure 2, thereby inhibiting the new
tumour formation.
Nanoparticle mediated therapy
Nanotechnology is the study of devices that are in the
dimensional range of 1-1000 nm. Nanotechnology has
been frequently used in oncology for the delivery of
drugs. The various methods of drug delivery in cancer
therapy using nanotechnology are nanoparticles, lipo-
somes, polymeric micelles, dendrimers, nanocantilevers,
carbon nanotubes and quantum dots. The concept of
using these nanoparticles for the purpose of drug deliv-
ery was first proposed by Widder, Senyi and colleagues
in 1978. The basic principle is that the drug is either
attached on or encapsulated within the nanoparticle.
These particles may have a polymer or metal coating
with magnetic cores. It is possible to attach or immobi-
lize the drug or an antibody on its surface and target it
to the desired site. If the nanoparticle is magnetic in
nature then it can be manipulated by applying a mag-
netic field from an external source. Magnetic drug tar-
geting is an emerging field in the cancer therapy. Gold
shell and iron core nanoparticle have been synthesized
to carry drugs (for example; Doxorubicin which binds to
amino group in the gold shell). Another method of drug
delivery has recently been developed by the scientists in
Brown University by coupling of magnetic nanoparticle
and gold nanoparticle with specific markers and creating
a twin nanoparticle [60-62].
They created a twin nanoparticle which specifically
binds to Her-2 receptors and then unloads the drug in
the breast cancer cells. This has been successfully
demonstrated in cancer cell lines. The nanoparticle can
be concentrated in the tumor region by magnetic prop-
erty and the specific drug or monoclonal antibody can be
targeted and released specifically at the tumor site with-
out affecting any other part of the body. This shall result
in minimum level of side effects and toxicity in the body.
Also the magnetite and gold are both stable and non
toxic. In this review we propose to design a twin nano-
particle i.e. iron core gold shell nanoparticle [63-66].
Design of SPIONS@Au nanoparticle
Gold nanoshell around super paramagnetic iron oxide
nanoparticles (SPIONs) can be synthesized with a gold
coating of approximately 0.4 to 0.5 nm thickness. The
gold-coated SPIONs (SPIONs@Au). Recently, it has
been demonstrated that in the absence of oscillating
magnetic field, both SPIONs and SPIONs@Au are not
particularly cytotoxic to mammalian cells in culture
[67,68]. However, nobody has tried these nanoparticles
for cancer therapy. We propose to tag the iron with
VEGF monoclonal antibody and gold with cancer stem
cell marker.
The twin nanoparticle can be mobilized to the tumour
region by applying external magnetic field so that it
does not affect the whole body as shown in Figure 3.
Table 3 List of cancer stem cell surface markers
Type of Cancer Cancer Stem Cell Marker References
Breast Cancer CD44/CD24, CD29, CD133, CD200 [44-47]
Pancreatic Cancer CD44, CD24, ESA, CD133, CXCR4 [48-50]
Bone Cancer Stro-1, CD105, CD44 [51]
Colorectal Cancer EpCAM, CD44, CD166, CD133 [52,53]
Prostate Cancer CD133, CD44, Integrin 12b1 [54]
Liver Cancer CD90, CD133 [55]
Brain tumour CD133, CD200 [56,57]
Head and Neck CD44, BMI-1 [58,59]
Ambasta et al. Vascular Cell 2011, 3:26
http://www.vascularcell.com/content/3/1/26
Page 4 of 8
The heat produced by this force of attraction can med-
iate the release of VEGF antibodies in the neighboring
tumor cells and blocking the angiogenic pathway. We
forecast a problem in locating cancer stem cell on the
superficial part of tumour, therefore, the use of magnet
can help the nanoparticle to invade to the interior parts
of tumour and locate the cancer stem cell. After locating
the cancer stem cell only, the nanoparticle will unfold
and release the VEGF monoclonal antibody to block
endothelial cells near cancer stem cell. This strategy will
be specific as normal angiogenesis is not blocked and
probability of occurrence of cancer stem cell marker on
normal cell is less. Even if the cancer stem cell marker
and normal cell marker overlaps, then the use of magnet
to tumour site tracks the nanoparticle only to tumour
site and not to the normal cells/tissues. Therefore using
these multiple ways, we can make the nanoparticle tar-
geting more specific.
Conclusion
Angiogenesis plays a critical role in the development of
cancer, its progression and metastasis. The tumor is com-
posed of heterogeneous cells. The tumor is believed to
have a stem cell niche which nurtures the cancer stem
cells leading to their division and differentiation into can-
cer cells. These cancer stem cells have found to be rich in
HIF-1a which is a transcriptional factor and it is acti-
vated in the hypoxic conditions in the tumor site and is
needed for it survival and proliferation. This HIF-1a
leads to the expression of VEGFR in the cells. VEGF is a
key regulator of angiogenesis in the tumors. Tumour
growth occurs due to the presence of cancer stem cell
combined with angiogenesis in the proximity of cancer
stem cells. Thus an effective method of controlling
tumour occurrence/reoccurrence could be targeting
endothelial cell near cancer stem cells. As we have
Figure 2 The above diagram shows that usually the cancer stem cells gives rise to new tumour in the presence of VEGF or
neovascularization in the proximity of cancer stem cells. The novel therapy procedure that targets the endothelial cell in the proximity of
cancer stem cell will lead to neither tumour growth nor metastasis.
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discussed above, the use of twin nanoparticle for target-
ing cancer stem cell niche and VEGF for inhibiting
angiogenesis in the cancer stem cell niche. This method
will lead to the destruction of CSCs and VEGF mediated
pathway of angiogenesis. This twin nanoparticle can be
made up of magnetite and gold and both can carry speci-
fic antibodies for CSC and VEGFR on their surface. Ear-
lier it was noted that iron nanoparticles can accumulate
in the body and can cause toxicity in the body. Recently,
iron core gold shell nanoparticle has been reported to be
less toxic. Also, the nanoparticles will be carrying a CSC
specific marker it will bind specifically to the Cancer
Stem cells and VEGF monoclonal antibody/inhibitor will
bind to endothelial cell present in/near the tumor site.
This can be done by the use of magnetic force which can
be applied from the outside. This can act as a remote
control to accumulate the nanoparticles in the desired
place, i.e. the tumor site. The heat produced by the mag-
netic attraction between the nanoparticle and the
external magnetic force can be used for the release of the
VEGF monoclonal antibodies into the tumor site. This
method can be very specific with very low toxicity in the
body. This new technology using twin nanoparticle offers
specific targeting of (VEGF inhibitors) drug to tumor
stem cell niche, thereby inhibiting tumour growth in the
cancer stem cell niche. This new technology can be bet-
ter than the classical therapy as the earlier inhibits angio-
genesis in tumour nonspecifically and not specifically on
cancer stem cell niche.
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